Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches

Video Series

Eva’s Treatment Journey With R/R MM

Videos

Medical experts explore tailored treatment strategies for patients with relapsed/refractory multiple myeloma using bispecific antibodies, featuring expert insights and a patient profile portrayal to guide clinical decision-making.

68-year-old male construction worker with a long history of multiple myeloma, managing multiple lines of treatment including BCMA-directed CAR T therapy, alongside a history of hypertension, respiratory infections, and type 2 diabetes, now receiving talquetamab.

John’s Journey with R/R MM

Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.

MonumenTAL: Key Efficacy Outcomes

Dr Mohan and Dr Mann discuss the current therapeutic landscape for relapsed/refractory multiple myeloma (R/R MM), alternative treatment strategies, and the real-world performance, advantages, and challenges of incorporating talquetamab into treatment protocols.

Implications of Talquetamab on the Current Treatment Landscape for R/R MM

Dr Mohan asks Dr Nadeem about the selection process among bispecific antibodies, the factors influencing decision-making, and the use of talquetamab, teclistamab, or elranatamab in specific patient subgroups, followed by a discussion with Dr Mann on next therapeutic steps if a patient experiences disease progression on talquetamab.

Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies

In this segment, Dr. Mohan asks Dr. Mann to summarize the key efficacy data from the MagnestisMM trials evaluating the use of elranatamab in relapsed/refractory multiple myeloma (R/R MM).

MagnestisMM: Key Efficacy Data and its Clinical Implications

In this segment, Dr Mohan asks Dr Nadeem about the real-world performance of elranatamab, its advantages and challenges in clinical practice, and the next therapeutic approach if a patient experiences disease progression on elranatamab.

Elranatamab: Real-World Experience and Sequencing

In this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.

Future of R/R MM: Emerging Agents

Eva’s Treatment Journey With R/R MM

EP: 1.John’s Journey with R/R MM

EP: 2.MonumenTAL: Key Efficacy Outcomes

EP: 3.Implications of Talquetamab on the Current Treatment Landscape for R/R MM

EP: 4.Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies

EP: 5.Eva’s Treatment Journey With R/R MM

EP: 6.MagnestisMM: Key Efficacy Data and its Clinical Implications

EP: 7.Elranatamab: Real-World Experience and Sequencing

EP: 8.Future of R/R MM: Emerging Agents

Newsletter